Evidence map›Paper›PMID 41909745›Full record

ReviewActa pharmaceutica Sinica. B2026

Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities.

Yuning Shi, Dazhi Feng, Jieya Zhou, Lihua Liu, Xinnan Li, Zhenwei Yuan, Jianbing Wu, Hong Yao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuning ShiDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Dazhi FengDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Jieya ZhouDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Lihua LiuDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Xinnan LiDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Zhenwei YuanDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Jianbing WuDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Hong YaoDepartment of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-binding proteins (RBPs) constitute central regulators of post-transcriptional gene expression and have been increasingly recognized as critical contributors to the pathogenesis of cancer, neurodegenerative disorders, and autoimmune diseases. However, in contrast to well-established drug targets such as kinases and G protein-coupled receptors, RBPs remain largely underexploited owing to their intrinsic structural heterogeneity, dynamic RNA interactions, and paucity of canonical ligand-binding pockets. In this review, we synthesize current knowledge on the roles of RBPs in disease, outline recent advances in the design of small-molecule modulators, and highlight innovative applications of high-throughput screening and chemical biology approaches for target identification and validation. We further discuss emerging concepts and challenges in translating RBP modulators into therapeutics, providing a forward-looking perspective on how these efforts may reshape small-molecule drug discovery in this evolving field.

Indexed as

Chemical biology approachesDiseaseDrug discoveryHigh-throughput screeningPost-transcriptional gene expressionRNA binding proteinsSmall-molecule modulatorsTarget identification

Identifiers

PMID41909745
PMCPMC13031079

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.